Cargando…
Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50...
Autores principales: | Kuchukulla, Ratnakar Reddy, Hwang, Injeoung, Park, Sang Won, Moon, Sojeong, Kim, Suhn Hyung, Kim, Sumin, Chung, Hwan Won, Ji, Mi-Jung, Park, Hyun-Mee, Kong, Gu, Hur, Wooyoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506414/ https://www.ncbi.nlm.nih.gov/pubmed/36145262 http://dx.doi.org/10.3390/ph15091041 |
Ejemplares similares
-
Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays
por: O. Salas, Cristian, et al.
Publicado: (2019) -
Synthesis and Pharmacophore Modelling of 2,6,9-Trisubstituted Purine Derivatives and Their Potential Role as Apoptosis-Inducing Agents in Cancer Cell Lines
por: Calderón-Arancibia, Jeannette, et al.
Publicado: (2015) -
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile
por: Lambertucci, Catia, et al.
Publicado: (2007) -
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia
por: Bertrand, Jeanluc, et al.
Publicado: (2022) -
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)